Hematopoietic Cell Transplantation Clinical Trials

3 recruiting

Hematopoietic Cell Transplantation Trials at a Glance

12 actively recruiting trials for hematopoietic cell transplantation are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Boston, Houston, and Cleveland. Lead sponsors running hematopoietic cell transplantation studies include Children's Hospital Medical Center, Cincinnati, Children's Oncology Group, and Case Comprehensive Cancer Center.

Browse hematopoietic cell transplantation trials by phase

Treatments under study

About Hematopoietic Cell Transplantation Clinical Trials

Looking for clinical trials for Hematopoietic Cell Transplantation? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematopoietic Cell Transplantation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematopoietic Cell Transplantation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital60 enrolled1 locationNCT07257419
Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Phase 1

Momelotinib During and After HCT in Myelofibrosis

MyelofibrosisHematopoietic Cell Transplantation (HCT)
Massachusetts General Hospital28 enrolled1 locationNCT07104799
Recruiting
Phase 3

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Early Phase 1

Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Case Comprehensive Cancer Center20 enrolled1 locationNCT04332341
Recruiting
Phase 2

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

AML (Acute Myeloid Leukemia)Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, China134 enrolled5 locationsNCT07304232
Recruiting
Not Applicable

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Oral MucositisMyeloablative Allogeneic Hematopoietic Cell TransplantationIntraoral Photobiomodulation Therapy+1 more
Dana-Farber Cancer Institute20 enrolled1 locationNCT05335434
Recruiting

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Chronic Lung DiseaseHematopoietic Cell Transplantation
University of Michigan Rogel Cancer Center375 enrolled6 locationsNCT05866302
Recruiting

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Solid TumorLeukemiaHematopoietic Cell Transplantation Recipient
Children's Oncology Group5,000 enrolled164 locationsNCT00736749
Recruiting
Phase 2

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation
Children's Hospital Medical Center, Cincinnati60 enrolled1 locationNCT05501756
Recruiting

A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

Hematopoietic Cell Transplantation
Duke University500 enrolled3 locationsNCT05090345
Recruiting
Not Applicable

The Effect of an Online ACT Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation

Hematopoietic Cell Transplantation RecipientAcceptance and Commitment Therapy
University of Social Sciences and Humanities, Warsaw192 enrolled1 locationNCT06266182